Recursion Pharmaceuticals, Inc.
Recursion Pharmaceuticals, Inc. (RXRX) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
rxrx · stock forecast · 10 analysts (3M) · FMP · updated Jun 8, 2026
Analyst Rating & Consensus
Based on 10 Wall Street analysts in the past 3 months
Hold
10 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$11.00
Consensus
$8.25
+148.5% upside
Low
$5.50
Median: $8.25 · Last Close: $3.32
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Consensus Target
$8.25
148.5% upside
High Target
$11
231.3%
Low Target
$5.5
65.7%
Current Price
$3.32
as of today
Based on analyst price targets, the RXRX stock price prediction for the next 12 months ranges from $5.5 to $11. The consensus RXRX price forecast of $8.25 implies 148.5% upside from the current price of $3.32.
Short-Term Price Prediction
Algorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $3.49 | ↑ 5.00% |
1-day model range: $3.46–$3.52. Peak: $3.52 (+5.00%).
Long-Term Stock Price Prediction
Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031
| Year | Avg Price | Change |
|---|---|---|
| 2027 | $2 | -50.0% |
| 2028 | $1 | -63.7% |
| 2029 | $1 | -69.2% |
| 2030 | $1 | -71.8% |
| 2031 | — | -73.1% |
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
BEARISH
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · RXRX · Jun 8, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2026-05-14 | Morgan Stanley | Maintains | Equal Weight→Equal Weight |
| 2026-05-07 | Needham | Maintains | Buy→Buy |
| 2026-04-30 | JP Morgan | Maintains | Overweight→Overweight |
| 2026-02-26 | B of A Securities | Maintains | Neutral→Neutral |
| 2026-02-26 | Needham | Maintains | Buy→Buy |
| 2025-12-17 | JP Morgan | Upgrade ↑ | Neutral→Overweight |
| 2025-09-11 | Needham | Maintains | Buy→Buy |
| 2025-07-08 | Needham | Maintains | Buy→Buy |
| 2025-06-16 | Morgan Stanley | Maintains | Equal Weight→Equal Weight |
| 2025-05-06 | Needham | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on Recursion Pharmaceuticals, Inc. (RXRX) stock. Of the recent 52 rating actions, 1 were upgrades and 2 were downgrades. 10 analysts currently cover RXRX.
Analyst Recommendation Trends
RXRX analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 1 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$62M
↓ 44.8% YoY
Revenue Next Year
$61M
↓ 0.5% YoY
EPS This Year
$-1.57
EPS Next Year
$-0.92
↓ 41.1% YoY
EPS ForecastReported vs Estimated
Analysts forecast RXRX EPS of $-1.57 for the current fiscal year, based on estimates from 6 analysts. The RXRX revenue forecast is $62M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The RXRX stock forecast is supported by two independent data sources: analyst consensus ratings from 10 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus RXRX price target is $8.25 (+148.5% upside), with an analyst consensus of Hold.
The RXRX short-term stock prediction for tomorrow is $3.49 (+5.00%). The RXRX stock price prediction for 2027 estimates an average of $2. The RXRX stock prediction for 2030 projects a range of $1–$1.
Recursion Pharmaceuticals, Inc. trades on NASDAQ under the ticker RXRX. The RXRX stock outlook for 2027 is broadly mixed, supported by a Hold consensus among 40% of covering analysts.
Frequently asked questions
RXRX forecast · 8 questionsAccording to 10 Wall Street analysts, the average 12-month RXRX price target is $8.25, with a high forecast of $11.00 and a low of $5.50. The median price target is shown in the chart above when available. This implies +148.5% potential upside from the current price of $3.32.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.